#ESMO21 Highlights on nivolumab in pretreated thymoma & thymic carcinoma: EORTC-ETOP NIVOTHYM st
1 Views
administrator
07/18/23
Nicolas Girard reports on key results from ESMO Congress 2021 on LBA66 - Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial
Produced by the European Society for Medical Oncology
http://oncologypro.esmo.org
-
Category
Show more
Facebook Comments
No comments found